DGAP-Adhoc: Aurubis AG: Aurubis AG exceeds expectations for Q1 and increases full-year forecast
2022. január 19., szerda, 13:38
DGAP-Ad-hoc: Aurubis AG / Key word(s): Change in Forecast/Quarter Results Aurubis AG exceeds expectations for Q1 and increases full-year forecast
As a result, the company is also increasing its forecast for the entire fiscal year 2021/22: The main reasons for the higher operating quarterly result compared to the prior-year period included a very good operating performance in all plants, considerably higher revenues from sulfuric acid sales, and an improved metal gain with increased metal prices, especially for the industrial metals (copper, tin, nickel, zinc). Furthermore, as of January 1, 2022, roughly 10 % higher treatment and refining charges for copper concentrates, a good ongoing level of refining charges for recycling materials, a significantly higher Aurubis copper premium, stronger demand for copper products, and substantially increased sulfuric acid prices will have a positive impact on the full-year result. Risks could arise from the influence of COVID-19 on the company"s production and product sales, as well as from energy price developments. IFRS consolidated earnings before taxes (EBT) in Q1 2021/22 amount to € 405 million according to preliminary calculations (previous year: € 226 million).
|
Language: | English |
Company: | Aurubis AG |
Hovestrasse 50 | |
20539 Hamburg | |
Germany | |
Phone: | +49 (0)40 / 78 83 - 31 78 |
Fax: | +49 (0)40 / 78 83 - 31 30 |
E-mail: | a.seidler@aurubis.com |
Internet: | www.aurubis.com |
ISIN: | DE0006766504 |
WKN: | 676650 |
Indices: | MDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard), Hamburg; Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1270422 |
End of Announcement | DGAP News Service |
1270422 19-Jan-2022 CET/CEST
Közzétételek - archívum
-
» Evonik Industries and Laxxon Medical see future in 3D screen printed pharmaceuticals
[2022.03.08. 15:02]
-
» Evonik und Laxxon Medical sehen Zukunftsmarkt für 3D-Druck von Tabletten
[2022.03.08. 15:02]
-
» "Game Changing" Technology Enables QR Code Integration with 3D Screen Printing
[2022.02.16. 17:31]
-
» Laxxon Medical to Participate in the 24th Annual Needham Virtual Growth Conference
[2022.01.07. 16:40]
-
» EQS-News: Focus Financial Partners Announces the Launch of Beryllus Capital in a Leading-Edge Joint Venture with the Hinduja Group
[2021.03.22. 12:45]
-
» DGAP-Adhoc: TRATON SE: TRATON und Navistar einig über Fortsetzung der Gespräche
[2020.10.16. 18:43]
-
» DGAP-Adhoc: TRATON SE: TRATON and Navistar agreement in principle
[2020.10.16. 18:43]
-
» EQS-News: International Cannabis Company Kaya Holdings, Inc. Enters into Strategic Partnership with U.S.-Israeli Cannabis Innovation Lab
[2020.07.22. 15:00]
-
» EQS-News: International Cannabis Company Kaya Holdings, Inc. and Greek Joint Venture Partner to Launch "Cannamo(TM)" Brand of CBD Pet Products
[2020.07.08. 17:15]